INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
SEC FORM 4/Grant or awardVerified data

Murphy Christopher M. reported ANAB

Chief Financial Officer · ANAPTYSBIO, INC · ANAPTYSBIO, INC — Restricted Stock Units

Side
A
Value
—
Shares
25.8K
Price
—
Executed
May 11, 2026
Disclosed
May 13, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
May 11 executedMay 13, 2026 disclosed

ANAB · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ANAB

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    GS
    Gray SusannahDirector
    ANABANAPTYSBIO, INC
    Grant or award
    		A—
    11.3K sh
    		Apr 27, 2026Apr 29, 2026
    traded Apr 27, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Disposition to issuer
    		D—
    2,321 sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Grant or award
    		A—
    133.4K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Disposition to issuer
    		D—
    133.4K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Grant or award
    		A—
    305.5K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Disposition to issuer
    		D—
    305.5K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Grant or award
    		A—
    379.6K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Disposition to issuer
    		D—
    379.6K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Grant or award
    		A—
    194.9K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Disposition to issuer
    		D—
    194.9K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Grant or award
    		A—
    9,200 sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Disposition to issuer
    		D—
    9,200 sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Grant or award
    		A—
    2,321 sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Grant or award
    		A—
    11.0K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    14
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Disposition to issuer
    		D—
    11.0K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    17
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Open-market sale
    		SELL$29K
    490 sh
    		Mar 27, 2026Mar 27, 2026
    traded Mar 27, 2026
    		+0dSEC FORM 4

    Evidence

    20
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Open-market sale
    		SELL$198K
    3,038 sh
    		Mar 27, 2026Mar 27, 2026
    traded Mar 27, 2026
    		+0dSEC FORM 4

    Evidence

    20
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Open-market sale
    		SELL$203K
    3,155 sh
    		Mar 27, 2026Mar 27, 2026
    traded Mar 27, 2026
    		+0dSEC FORM 4

    Evidence

    20
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Open-market sale
    		SELL$215K
    3,662 sh
    		Mar 27, 2026Mar 27, 2026
    traded Mar 27, 2026
    		+0dSEC FORM 4

    Evidence

    20
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Open-market sale
    		SELL$164K
    2,592 sh
    		Mar 27, 2026Mar 27, 2026
    traded Mar 27, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002005986-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    May 11, 2026
    Published
    May 13, 2026
    Ingested by INSIDER
    Nov 5, 03:59 UTC
    Last re-read
    Nov 5, 03:59 UTC

    Extracted facts

    Filer
    Murphy Christopher M.
    Role
    Chief Financial Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    ANAPTYSBIO, INC — Restricted Stock Units
    Ticker
    ANAB
    Shares
    25.8K
    Price per share
    $0
    Execution date (reported)
    May 11, 2026
    Owned after transaction
    25.8K shares
    Days from execution to publication
    2

    What this establishes

    Murphy Christopher M. filed this Form 4 reporting a grant or award of ANAB on May 11, 2026. It became public on May 13, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Murphy Christopher M.cik:0002005986
    Issuer
    ANAPTYSBIO, INCcik:0001370053

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.